AIDS Medicines: In Development, Drugs and Vaccines

Anti-infectives
DRUG NAME COMPANY INDICATION U.S. DEVELOPMENT STATUS
FIAC Oclassen Pharmaceutical CMV infection Phase I/II
Fiacitabine (San Rafael, CA)
Mycostatin~t Bristol-Myers Squibb prevention of oral candidiasis Phase III
Pastille (New York, NY)
Nystatin Pastille
NebuPent~ LyphoMed PCP treatment Phase III
Aerosol Pentamidine (Rosemont, IL) (Orphan Drug)
Isethionate
Nizoral~ Janssen Pharmaceutica candida esophagitis Phase III
Ketoconazole (Piscataway, NJ)
(suspension)
Ornidyl Merrell Dow PCP treatment IND approved
Eflornithine (Cincinnati, OH) (Orphan Drug)
Piritrexim Burroughs Wellcome PCP treatment Phase I/II
(Rsch. Triangle Park, NC)
Pneumopent' Fisons Corporation PCP prophylaxis NDA submitted
Aerosol Pentamidine (Bedford, MA)
Isethionate
Rifabutin Adria Labs MAI prophylaxis Phase II
(Columbus, OH)
Spiramycin Rhone-Poulenc cryptosporidial diarrhea Phase II/III
Pharmaceuticals
(Princeton, NJ)
Sporanox~ Janssen Pharmaceutica maintenance therapy for Phase III
Itraconazole- (Piscataway, NJ) cryptococcal meningitis,
R51211 histoplasmosis
TI-23 Teijin Ltd. CMV infection Phase I
CMV Monoclonal (Tokyo, Japan)
Trimetrexate Warner-Lambert PCP treatment Treatment IND;
with Leukovorint (Morris Plains, NJ) Phase III
Other
DRUG NAME COMPANY INDICATION U.S. DEVELOPMENT STATUS
Megace~ t Bristol-Myers Squibb treatment of anorexia and cachexia Phase II/III
Megestrol Acetate (New York, NY) associated with AIDS
Mesalamine Norwich Eaton inflammatory bowel syndrome Phase I/II
(Norwich, NY) associated with HIV infection, ARC,
AIDS
Sandostatin~ t Sandoz HIV-related diarrhea Phase II/III
Somatostatin (East Hanover, NJ)
Vaccines
VACCINE NAME COMPANY INDICATION U.S. DEVELOPMENT STATUS
HIVAC-le Bristol-Myers Squibb HIV negative, early HIV infection Phase II
(New York, NY)
Salk HIV Immunization Products early HIV infection Phase Il/II
Immunogen~ (Horsham, PA)
VaxSyn~ MicroGeneSys HIV negative Phase I/II as vaccine
HIV-1 (gp 160) (W est Haven, CT)........................
early HIV infection Phase I as therapeutic
The content of this survey has been obtained through government and industry sources (including FDA and NIH) based on the latest

information. Survey current as of February 10, 1990. The information may not be comprehensive. For more specific information about
a particular product, contact the individual company directly. For general information, contact the Pharmaceutical Manufacturers
Association at [phone]. (If you are not receiving the AIDS survey regularly but would like to, please send your request in writing
to Editor, "AIDS Medicines in Development, "Pharmaceutical Manufacturers Association, 1100 15th St., NW, Washington, DC 20005.)